Spotlight
Topic
Brand Insights
Subscribe
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Liberated?
Article
Pharmaceutical Executive
Pharmaceutical ExecutivePharmaceutical Executive-04-01-2001
Volume 0
Issue 0
Patents before profits. That soundbite snagged my ears and turned my full attention to the CNN business report. I recognized the voice and the face}Ray Gilmartin, chairman of Merck. Calmly and reasonably, he explained how extraordinary circumstances in the developing world demand that his company uncouple the normally fused objectives of high profitability and unwavering patent protection.
Articles in this issue
Annual Reports: Size Doesn't Matter
Internet DTC - Minding Your P's & Q's
Regulation: Two-Track Plan
Policy: Tectonic Shift
Liberated?
A Matter of Taste
Partnerships: Bargaining Biotechs
Pediatric Mandate
Genentech's Passion for Patients
Regulation: OK After All
Beyond Training
Balancing Haves & Have-Nots
The Changing OTC Landscape
Recent Videos
Related Content
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Podcast
Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
